Skip to main content

Table 2 Pooled relative risks of CVDs mortality for categorical and continuous analyses in subgroups

From: Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies

Sub-groups Triglyceride group (mg/dl) Per 1 mmol/L TG
<90 90-146 150-199 ≥200  
N* RR (95% CI) N* RR† N* RR (95% CI) N* RR (95% CI) N* RR (95% CI)
Age (year)
  <50 3 0.84 (0.74, 0.96) 4 1.00 4 1.21 (1.06, 1.40) 3 1.20 (0.94, 1.53) 10 1.11 (1.01, 1.22)
  ≥50 7 0.85 (0.68, 1.05) 8 1.00 8 1.08 (0.90, 1.30) 5 1.30 (0.99, 1.69) 12 1.15 (1.09, 1.22)
  P value   0.956     0.338   0.664   0.488
Gender
  Male 5 0.86 (0.67, 1.09) 5 1.00 5 1.06 (0.89, 1.30) 5 1.31 (1.12, 1.15) 18 1.10 (1.04, 1.15)
  Female 3 0.76 (0.64, 0.90) 3 1.00 3 1.37 (1.09, 1.71) 2 2.08 (1.44, 3.00) 9 1.40 (1.22, 1.59)
  Mixed 4 1.01 (0.65, 1.56) 6 1.00 6 1.14 (1.10, 1.31) 4 1.26 (0.99, 1.60) 4 1.16 (1.08, 1.25)
  P value   0.416     0.100   0.023   0.001
Follow-up (year)
  <12 6 0.81 (0.71, 0.91) 6 1.00 6 1.01 (0.84, 1.19) 4 1.25 (0.84, 1.84) 11 1.14 (1.06, 1.22)
  ≥12 4 0.79 (0.61, 1.02) 4 1.00 6 1.27 (1.13, 1.44) 4 1.25 (1.01, 1.54) 11 1.11 (1.02, 1.21)
  P value   0.473     0.025   0.992   0.694
Fast status
  Fast 6 0.89 (0.71, 1.12) 7 1.00 7 1.15 (0.98, 1.35) 4 1.42 (1.22, 1.64) 10 1.10 (1.04, 1.17)
  Nonfast 3 1.00 (0.65, 1.54) 4 1.00 4 1.14 (0.85, 1.46) 4 1.11 (0.85, 1.46) 7 1.12 (1.01, 1.23)
  Others§ 1 0.80 (0.69, 0.93) 1 1.00 1 1.15 (0.90, 1.45) 0 - 5 1.19 (1.00, 1.41)
  P value   0.646     0.843   0.122   0.821
Geographic location
  Europe/America 7 0.86 (0.73, 1.01) 8 1.00 8 1.17 (1.00, 1.37) 5 1.22 (1.02, 1.55) 18 1.11 (1.05, 1.17)
  Asia-Pacific 3 0.80 (0.70, 0.92) 4 1.00 4 1.20 (0.93, 1.35) 3 1.20 (0.82, 1.77) 4 1.26 (1.05, 1.52)
  P value   0.509     0.729   0.847   0.205
Quality score
  <7 4 0.76 (0.65, 0.90) 5 1.00 5 1.01 (0.80, 1.29) 4 1.24 (0.91, 1.68) 8 1.16 (1.04, 1.29)
  7-9 6 0.92 (0.77, 1.05) 7 1.00 7 1.23 (1.09, 1.38) 4 1.25 (0.98, 1.60) 14 1.11 (1.04, 1.19)
  P value   0.100     0.167   0.961   0.509
Sample size
  <4000 7 0.84 (0.70, 1.02) 7 1.00 7 1.10 (0.91, 1.32) 4 1.49 (1.21, 1.80) 10 1.14 (1.06, 1.22)
  ≥4000 3 0.83 (0.71, 0.97) 5 1.00 5 1.18 (1.02, 1.38) 4 1.12 (0.84, 1.45) 12 1.13 (1.04, 1.22)
  P value   0.910     0.541   0.100   0.883
Free of CVDs at baseline
  Yes 6 0.85 (0.76, 0.96) 7 1.00 7 1.12 (0.92, 1.36) 6 1.20 (0.96, 1.50) 13 1.11 (1.04, 1.20)
  No 4 0.88 (0.67, 1.56) 5 1.00 5 1.16 (1.00, 1.34) 2 1.43 (1.16, 1.76) 9 1.16 (1.09, 1.24)
  P value   0.832     0.811   0.265   0.371
Adjustment
  Minimally 4 0.72 (0.55, 0.94) 5 1.00 5 1.44 (1.16, 1.78) 4 1.52 (1.14, 2.02) 7 1.15 (1.08, 1.22)
  Maximally 4 0.87 (0.77, 0.98) 5 1.00 5 1.24 (1.05, 1.46) 4 1.29 (1.01, 1.65) 7 1.05 (0.99, 1.11)
  P value   0.207     0.271   0.398   0.033
Adjustment for TC
  Yes 4 0.85 (0.77, 0.94) 4 1.00 4 1.24 (1.07, 1.43) 3 1.27 (0.94, 1.71) 14 1.09 (1.03, 1.16)
  No 6 0.82 (0.61, 1.09) 8 1.00 8 1.06 (0.89, 1.26) 5 1.25 (0.97, 1.61) 8 1.21 (1.10, 1.34)
  P value   0.810     0.169   0.927   0.078
Adjustment for HDL
  Yes 3 0.81 (0.72, 0.91) 3 1.00 3 1.23 (1.04, 1.47) 1 1.52 (1.14, 2.02) 3 1.10 (1.03, 1.19)
  No 7 0.84 (0.68, 1.04) 9 1.00 9 1.09 (0.94, 1.27) 7 1.21 (1.00, 1.47) 19 1.13 (1.06, 1.20)
  P value   0.734     0.313   0.200   0.679
  1. *The number of cohorts.
  2. †Reference group.
  3. §Others included mixed and unknown ones.
  4. RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
  5. TG: triglycerides; TC: total cholesterol.